Lifecore Biomedical, Inc. (LFCR)
NASDAQ: LFCR · Real-Time Price · USD
7.28
-0.21 (-2.80%)
Dec 27, 2024, 4:00 PM EST - Market closed
Lifecore Biomedical Income Statement
Financials in millions USD. Fiscal year is June - May.
Millions USD. Fiscal year is Jun - May.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
---|---|---|---|---|---|---|---|
Period Ending | Aug '24 Aug 25, 2024 | May '24 May 26, 2024 | May '23 May 28, 2023 | May '22 May 29, 2022 | May '21 May 30, 2021 | May '20 May 31, 2020 | 2019 - 2015 |
Revenue | 128.44 | 128.26 | 103.27 | 111.27 | 100.87 | 160.07 | Upgrade
|
Revenue Growth (YoY) | 23.42% | 24.20% | -7.19% | 10.31% | -36.98% | -71.29% | Upgrade
|
Cost of Revenue | 83.94 | 86.41 | 75.28 | 72.2 | 61.94 | 123.68 | Upgrade
|
Gross Profit | 44.51 | 41.85 | 27.99 | 39.07 | 38.94 | 36.39 | Upgrade
|
Selling, General & Admin | 44.75 | 40.46 | 38.97 | 34.66 | 29.32 | 38.17 | Upgrade
|
Research & Development | 8.62 | 8.58 | 8.74 | 7.84 | 6.68 | 7.58 | Upgrade
|
Operating Expenses | 53.37 | 49.04 | 47.71 | 42.5 | 36.01 | 45.75 | Upgrade
|
Operating Income | -8.86 | -7.19 | -19.72 | -3.43 | 2.93 | -9.37 | Upgrade
|
Interest Expense | -19.52 | -18.09 | -17.58 | -15.47 | -8.93 | -4.65 | Upgrade
|
Interest & Investment Income | - | - | - | - | 0.05 | 0.07 | Upgrade
|
Other Non Operating Income (Expenses) | 37.12 | 36.45 | -0.81 | 6.57 | -10.97 | -0.2 | Upgrade
|
EBT Excluding Unusual Items | 8.74 | 11.17 | -38.11 | -12.33 | -16.92 | -14.14 | Upgrade
|
Merger & Restructuring Charges | -2.96 | -1.66 | -4.18 | -8.36 | -13.36 | -4.05 | Upgrade
|
Impairment of Goodwill | - | - | - | - | - | -7.9 | Upgrade
|
Gain (Loss) on Sale of Assets | - | - | 2.11 | - | - | - | Upgrade
|
Asset Writedown | - | - | - | - | - | -6.35 | Upgrade
|
Other Unusual Items | - | - | -23.74 | - | -1.11 | -1.2 | Upgrade
|
Pretax Income | 5.78 | 9.51 | -63.93 | -20.69 | -29.79 | -30.65 | Upgrade
|
Income Tax Expense | 0.07 | 0.18 | 0.31 | -5.21 | -6.35 | -8.77 | Upgrade
|
Earnings From Continuing Operations | 5.71 | 9.33 | -64.24 | -15.48 | -23.44 | -21.87 | Upgrade
|
Earnings From Discontinued Operations | 0.83 | 2.68 | -35.33 | -101.24 | -8.86 | -16.32 | Upgrade
|
Net Income to Company | 6.54 | 12.01 | -99.56 | -116.72 | -32.29 | -38.19 | Upgrade
|
Net Income | 6.54 | 12.01 | -99.56 | -116.72 | -32.29 | -38.19 | Upgrade
|
Net Income to Common | 6.54 | 12.01 | -99.56 | -116.72 | -32.29 | -38.19 | Upgrade
|
Shares Outstanding (Basic) | 31 | 30 | 30 | 29 | 29 | 29 | Upgrade
|
Shares Outstanding (Diluted) | 37 | 37 | 30 | 29 | 29 | 29 | Upgrade
|
Shares Change (YoY) | 21.90% | 22.36% | 1.67% | 0.59% | 0.45% | 1.94% | Upgrade
|
EPS (Basic) | 0.21 | 0.39 | -3.32 | -3.96 | -1.10 | -1.31 | Upgrade
|
EPS (Diluted) | 0.17 | 0.32 | -3.32 | -3.97 | -1.10 | -1.31 | Upgrade
|
Free Cash Flow | -8.79 | -18.14 | -38.92 | -52.53 | -8.75 | -43.73 | Upgrade
|
Free Cash Flow Per Share | -0.24 | -0.49 | -1.30 | -1.78 | -0.30 | -1.50 | Upgrade
|
Gross Margin | 34.65% | 32.63% | 27.10% | 35.11% | 38.60% | 22.73% | Upgrade
|
Operating Margin | -6.90% | -5.60% | -19.10% | -3.08% | 2.91% | -5.85% | Upgrade
|
Profit Margin | 5.09% | 9.37% | -96.41% | -104.89% | -32.01% | -23.86% | Upgrade
|
Free Cash Flow Margin | -6.84% | -14.14% | -37.69% | -47.21% | -8.68% | -27.32% | Upgrade
|
EBITDA | -0.67 | 1.17 | -7.04 | 14.23 | 8.13 | -1.27 | Upgrade
|
EBITDA Margin | -0.52% | 0.91% | -6.82% | 12.79% | 8.06% | -0.79% | Upgrade
|
D&A For EBITDA | 8.18 | 8.36 | 12.68 | 17.66 | 5.2 | 8.1 | Upgrade
|
EBIT | -8.86 | -7.19 | -19.72 | -3.43 | 2.93 | -9.37 | Upgrade
|
EBIT Margin | -6.90% | -5.60% | -19.10% | -3.08% | 2.91% | -5.85% | Upgrade
|
Effective Tax Rate | 1.21% | 1.92% | - | - | - | - | Upgrade
|
Revenue as Reported | 128.44 | 128.26 | 103.27 | 111.27 | - | - | Upgrade
|
Advertising Expenses | - | - | 0.01 | 0.01 | 0 | 0.1 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.